Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230975 | 0.86 | CHRNA7 (0.34) | CHRNA7KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6398977 | 0.85 | KDR (0.34) | CHRNA7KCNH2KDRFLT1 | |
| SCHEMBL6205699 | 0.85 | MAP2K1 (0.37) | CHRNA7KCNH2CYP3A4KDRFLT1 | |
| SCHEMBL6207867 | 0.84 | CHRNA7 (0.33) | CHRNA7KCNH2CYP3A4CHRNA1CHRNB2 | |
| SCHEMBL6399685 | 0.83 | ELANE (0.36) | CYP3A4KDRFLT1 | |
| SCHEMBL6207914 | 0.83 | CHRNA7 (0.51) | CHRNA7KCNH2CYP3A4CHRNA1CHRNB2 | |
| SCHEMBL6186306 | 0.82 | CHRNA7 (0.30) | CHRNA7KCNH2CYP3A4KDRFLT1 | |
| SCHEMBL6207184 | 0.82 | FLT1 (0.39) | KDRFLT1 | |
| SCHEMBL6207302 | 0.81 | PDCD1 (0.39) | CHRNA7KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6403620 | 0.81 | CHRNA7 (0.48) | CHRNA7KCNH2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | CHRNA7 4667/4885KCNH2 3852/4885CYP3A4 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.